- Home
- STOK
as 07-26-2024 4:00pm EST
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 707.8M | IPO Year: | 2019 |
| Target Price: | $21.67 | AVG Volume (30 days): | 671.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.35 - $17.58 | Next Earning Date: | 08-05-2024 |
| Revenue: | $7,845,000 | Revenue Growth: | -46.10% |
| Revenue Growth (this year): | 66.03% | Revenue Growth (next year): | 20.34% |
Stock Insider Trading Activity of Stoke Therapeutics Inc. (STOK)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nash Huw M. | STOK | Chief Business Officer | Jul 2 '24 | Sell | $13.90 | 33 | $458.70 | 0 | SEC Form 4 |
| Nash Huw M. | STOK | Chief Business Officer | Jul 2 '24 | Sell | $13.10 | 2,467 | $32,320.17 | 33 | SEC Form 4 |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Jul 1 '24 | Sell | $13.75 | 10,000 | $137,458.00 | 2,485 | SEC Form 4 |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Jun 3 '24 | Sell | $15.78 | 103 | $1,625.34 | 2,485 | SEC Form 4 |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Jun 3 '24 | Sell | $15.21 | 9,897 | $150,560.09 | 2,588 | SEC Form 4 |
| Nash Huw M. | STOK | COO & CBO | May 20 '24 | Sell | $15.39 | 50,000 | $769,500.00 | 0 | SEC Form 4 |
| Kaye Edward M. MD | STOK | CEO | May 20 '24 | Sell | $15.39 | 39,686 | $610,783.41 | 29,664 | SEC Form 4 |
| Kaye Edward M. MD | STOK | CEO | May 20 '24 | Sell | $16.05 | 2,664 | $42,745.74 | 27,000 | SEC Form 4 |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | May 20 '24 | Sell | $15.04 | 8,599 | $129,327.24 | 2,598 | SEC Form 4 |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | May 1 '24 | Sell | $11.37 | 10,000 | $113,653.00 | 2,485 | SEC Form 4 |
| Skorpios Trust | STOK | 10% Owner | Apr 17 '24 | Sell | $11.60 | 3,600,000 | $41,760,000.00 | 10,843,681 | SEC Form 4 |
| Nash Huw M. | STOK | COO & CBO | Apr 1 '24 | Sell | $13.61 | 400 | $5,444.00 | 0 | SEC Form 4 |
| Nash Huw M. | STOK | COO & CBO | Apr 1 '24 | Sell | $13.22 | 60,929 | $805,767.75 | 400 | SEC Form 4 |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Apr 1 '24 | Sell | $13.23 | 9,426 | $124,684.30 | 2,485 | SEC Form 4 |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Mar 28 '24 | Sell | $13.19 | 5,026 | $66,286.91 | 2,698 | SEC Form 4 |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Mar 28 '24 | Sell | $13.81 | 100 | $1,381.00 | 2,598 | SEC Form 4 |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Mar 15 '24 | Sell | $6.10 | 4,116 | $25,101.84 | 11,469 | SEC Form 4 |
| Tulipano Stephen J | STOK | CFO | Mar 15 '24 | Sell | $6.10 | 4,116 | $25,101.84 | 20,746 | SEC Form 4 |
| Nash Huw M. | STOK | COO & CBO | Mar 15 '24 | Sell | $6.10 | 4,116 | $25,101.84 | 11,329 | SEC Form 4 |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Mar 15 '24 | Sell | $6.10 | 2,349 | $14,325.61 | 7,724 | SEC Form 4 |
| Kaye Edward M. MD | STOK | CEO | Mar 15 '24 | Sell | $6.10 | 11,150 | $67,999.39 | 69,350 | SEC Form 4 |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Mar 1 '24 | Sell | $7.75 | 10,000 | $77,469.00 | 2,485 | SEC Form 4 |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Feb 1 '24 | Sell | $4.80 | 10,000 | $47,991.00 | 6,981 | SEC Form 4 |
| Ticho Barry | STOK | Chief Medical Officer | Jan 2 '24 | Sell | $5.74 | 10,000 | $57,352.00 | 16,981 | SEC Form 4 |
Latest Stoke Therapeutics Inc. News
STOK Breaking Stock News: Dive into STOK Ticker-Specific Updates for Smart Investing
Business Wire
10 days ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire
a month ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Simply Wall St.
a month ago
We Think Stoke Therapeutics (NASDAQ:STOK) Can Afford To Drive Business Growth
MT Newswires
a month ago
Stoke Therapeutics Files Registration Statement For Sale of 10.8 Million Shares by Stockholders
Business Wire
2 months ago
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
GuruFocus.com
2 months ago
Insider Sale: CEO Edward M. Kaye of Stoke Therapeutics Inc (STOK) Sells 42,350 Shares
MT Newswires
2 months ago
Stoke Therapeutics Insider Sold Shares Worth $653,529, According to a Recent SEC Filing
Business Wire
2 months ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Compare STOK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STOK Stoke Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.